Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SGN CD48A

Drug Profile

SGN CD48A

Alternative Names: SGN-CD48A

Latest Information Update: 24 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Seattle Genetics
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins
  • Mechanism of Action Cell death stimulants; Mitosis inhibitors; Tubulin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple myeloma

Most Recent Events

  • 23 Aug 2019 Seattle Genetics terminates a phase I trial in Multiple myeloma (Second-line therapy or greater) in USA (IV) due to overall benefit/risk profile (NCT03379584)
  • 21 Apr 2018 Pharmacodynamics data from preclinical studies in Cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
  • 20 Feb 2018 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater) in USA (IV) (NCT03379584)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top